Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Single Escalating Dose Study of Subcutaneous Certolizumab Pegol (CZP) to Evaluate the Pharmacokinetics and Safety of CZP in Healthy Chinese Subjects

NCT02365948 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.

NCT NCT02365948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02365948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Single Escalating Dose Study of Subcutaneous Certolizumab Pegol (CZP) to Evaluate the Pharmacokinetics and Safety of CZP in Healthy Chinese Subjects
Lead sponsor
UCB Pharma SA
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2015
Completion date
August 31, 2015
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects